← Leaderboards
Kathleen A Stringer
University Of Michigan At Ann Arbor
$5,904,083
Attributed
$6,928,951
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $882.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,221,594 · 6
FDA$1,707,357 · 1
By mechanism
R01$2,911,873 · 2
R35$2,364,219 · 1
R42$833,044 · 1
R15$463,337 · 1
R21$256,785 · 1
R41$99,693 · 1
Top collaborators
- Kurt Robert Schumacher4 shared
- Nathan I Shapiro1 shared
- Tamar Sofer1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Steven Lynn Kunkel$20,708,735
- Benjamin Herschel Singer$4,763,896
- Pauline K Park$1,302,958
- Robert C Hyzy$5,668,847
- Mark R Opp$9,091,391
Others in their field
Top investigators on “Pharmacotherapy”
- Carol Nesel · Westat$116,355,411
- Barbara Driver · Westat, Inc.$62,829,804
- Ronald B Corley · Boston University Medical Campus$43,000,000
- Anastassios G Pittas · Tufts Medical Center$42,391,504
- Edward V Nunes · Columbia University Health Sciences$36,956,141
- Vance G Fowler · Duke University$30,735,128
Research focus
PharmacotherapyMetabolomicsHeterogeneityLevocarnitineSepsisPharmaceutical PreparationsEffective TherapyMetabolicMortalityFuturePhenotypePrecision MedicineResponseMetabolismPublic HealthDesignAcylcarnitineNovel TherapeuticsPharmacometabolomicsCarnitineDefectCritical IllnessHazardClinical Trials
Grant awards (20)
Translational Metabolomics in Critical Care$438,672
R35 · FY2025 · GM · contact PI
Genetically Linked Metabolites of Sepsis Severity and Mortality$256,785
R21 · FY2025 · HL · contact PI
Translational Metabolomics in Critical Care$382,707
R35 · FY2024 · GM · contact PI
Translational Metabolomics in Critical Care$382,707
R35 · FY2023 · GM · contact PI
Translational Metabolomics in Critical Care$382,707
R35 · FY2022 · GM · contact PI
IND119678 Phase II Safety & Efficacy of Inhaled Activase for Acute Plastic Bronchitis 12-10-14$207,357
R01 · FY2022 · FD · contact PI
Translational Metabolomics in Critical Care$12,012
R35 · FY2022 · GM · contact PI
Translational Metabolomics in Critical Care$382,707
R35 · FY2021 · GM · contact PI
IND119678 Phase II Safety & Efficacy of Inhaled Activase for Acute Plastic Bronchitis 12-10-14$500,000
R01 · FY2020 · FD · contact PI
Translational Metabolomics in Critical Care$382,707
R35 · FY2020 · GM · contact PI
L-Carnitine Pharmacometabolomics in Sepsis (CaPS)$298,421
R01 · FY2019 · GM · contact PI
IND119678 Phase II Safety & Efficacy of Inhaled Activase for Acute Plastic Bronchitis 12-10-14$500,000
R01 · FY2018 · FD · contact PI
L-Carnitine Pharmacometabolomics in Sepsis (CaPS)$298,421
R01 · FY2018 · GM · contact PI
L-Carnitine Pharmacometabolomics in Sepsis (CaPS)$303,693
R01 · FY2017 · GM · contact PI
IND119678 Phase II Safety & Efficacy of Inhaled Activase for Acute Plastic Bronchitis 12-10-14$500,000
R01 · FY2016 · FD · contact PI
L-Carnitine Pharmacometabolomics in Sepsis (CaPS)$303,981
R01 · FY2016 · GM · contact PI
Pulmonary Formulation of tPA for Plastic Bronchitis$463,337
R15 · FY2010 · HD · contact PI
Safety of Lung Delivered Tissue Plasminogen Activator$364,440
R42 · FY2006 · HL · contact PI
Safety of Lung Delivered Tissue Plasminogen Activator$468,604
R42 · FY2005 · HL
Lung Delivery of Nebulized Tissue Plasminogen Activator$99,693
R41 · FY2003 · HL